Supplementary material

Phytochemical and Micro-Morphological Characterization of *Atraphaxis pyrifolia* Bunge Growing in the Republic of Kazakhstan

Alima Abilkassymova 1,2,3, Raushan Kozykeyeva 3,4 , Jennyfer Andrea Aldana-Mejía 3, Sebastian John Adams 3 , Ubaidilla Datkhayev 2, Aknur Turgumbayeva 1,5, Kulpan Orynbassarova 4, Seethapathy G. Saroja 3 , Ikhlas A. Khan 3,6 and Samir A. Ross 2,3,6,*

[1] Higher School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan; abilkasymova_a@mail.ru (A.A.); turgumbayeva.aknur@med-kaznu.com (A.T.)
[2] School of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan; u.datkhayev@gmail.com
[3] National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, Oxford, MS 38677, USA; nar_rau@mail.ru (R.K.); jaaldana@olemiss.edu (J.A.A.-M.); jasabest@olemiss.edu (S.J.A.); seethapathy.gs@gmail.com (S.G.S.); ikhan@olemiss.edu (I.A.K.)
[4] Department of Pharmacognosy, Faculty of Pharmacy, South Kazakhstan Medical Academy, Shymkent 160019, Kazakhstan; kulpan_ok@mail.ru
[5] School of Life Sciences, University of Westminster, London W1W 6UW, UK
[6] Department of Biomolecular Sciences, Division of Pharmacognosy, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA

Table of contents

Figure S 1. GC-MS spectra of hexane extract of *A. pyrifolia* leaves. 3
Figure S 2. ^{1}H and ^{13}C NMR (MeOD; 500 MHz) of Compound 1 (8-*O*-acetyl-7-*O*-methyl-3-*O*-α-L-rhamnopyranosylgossypetin). 4
Figure S 3. HSQC and HMBC NMR correlations (MeOD; 500 MHz) of Compound 1 (8-*O*-acetyl-7-*O*-methyl-3-*O*-α-L-rhamnopyranosylgossypetin). 5
Figure S 4. ^{1}H and ^{13}C NMR (MeOD; 500 MHz) of Compound **2** (5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxo-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-8-yl acetate)....6
Figure S 5. HSQC and HMBC correlations (MeOD; 500 MHz) of Compound **2** (5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxo-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-8-yl acetate). 7
Figure S 6. ^{1}H and ^{13}C NMR correlations (MeOD; 500 MHz) of Compound **3** (7-*O*-methyl-3-*O*-α-L-rhamnopyranosylgossypetin). 8
Figure S 7. HSQC and HMBC NMR correlations (MeOD; 500 MHz) of Compound **3** (7-*O*-methyl-3-*O*-α-L-rhamnopyranosylgossypetin). 9
Figure S 8. ^{1}H and ^{13}C NMR correlations (MeOD; 400 MHz) of Compound **4** (5,8-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one). 10

Figure S 9. HSQC and HMBC NMR correlations (MeOD; 400 MHz) of Compound **4** (5,8-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one). 11
Figure S 10. HR-ESI-MS $[M + H]^+$ data of Compound **1**. 12
Figure S 11. HR-ESI-MS $[M^+H]^+$ data of Compound **2**. 13
Figure S 12. HR-ESI-MS $[M^+H]^-$ data of Compound **3**. 14
Figure S 13. HR-ESI-MS $[M^+H]^-$ data of Compound **4**. 15




Figure S 1. GC-MS spectra of hexane extract of *A. pyrifolia* leaves.




Figure S 2. ^{1}H and ^{13}C NMR (MeOD; 500 MHz) of Compound **1** (8-*O*-acetyl-7-*O*-methyl-3-*O*-α-L-rhamnopyranosylgossypetin).




Figure S 3. HSQC and HMBC NMR correlations (MeOD; 500 MHz) of Compound **1** (8-*O*-acetyl-7-*O*-methyl-3-*O*-*α*-L-rhamnopyranosylgossypetin).




Figure S 4. ^{1}H and ^{13}C NMR (MeOD; 500 MHz) of Compound **2** (5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxo-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-8-yl acetate).




Figure S 5. HSQC and HMBC correlations (MeOD; 500 MHz) of Compound **2** (5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxo-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-8-yl acetate).




Figure S 6. [1]H and [13]C NMR correlations (MeOD; 500 MHz) of Compound **3** (7-*O*-methyl-3-*O*-*α*-L-rhamnopyranosylgossypetin).




Figure S 7. HSQC and HMBC NMR correlations (MeOD; 500 MHz) of Compound **3** (7-*O*-methyl-3-*O*-*α*-L-rhamnopyranosylgossypetin).




Figure S 8. [1]H and [13]C NMR correlations (MeOD; 400 MHz) of Compound **4** (5,8-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one).




Figure S 9. HSQC and HMBC NMR correlations (MeOD; 400 MHz) of Compound **4** (5,8-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-3-(((3S,4S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one).




Figure S 10. HR-ESI-MS $[M^{+}H]^{+}$ data of Compound **1**.




Figure S 11. HR-ESI-MS $[M^{+}H]^{+}$ data of Compound **2**.




Figure S 12. HR-ESI-MS $[M^{+}H]^{-}$ data of Compound **3**.




Figure S 13. HR-ESI-MS $[M^{+}H]^{-}$ data of Compound **4**.